Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834098 | 0.81 | PPARG (0.55) | PPARGMAPTMCL1KDM4ECYP19A1 | |
| SCHEMBL15828870 | 0.74 | MAPT (0.52) | PPARGMAPTMCL1KDM4EALDH1A1 | |
| SCHEMBL22091734 | 0.68 | CAPN1 (0.68) | PPARGMAPTCYP19A1ALDH1A1 | |
| SCHEMBL22099884 | 0.68 | CAPN1 (0.68) | PPARGMAPTCYP19A1ALDH1A1 | |
| SCHEMBL21783138 | 0.67 | MCL1 (0.67) | PPARGMCL1ALDH1A1POLBKMT2A | |
| SCHEMBL5208299 | 0.65 | MAPT (1.00) | PPARGMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL12291322 | 0.63 | PPARG (0.60) | PPARGMAPTMCL1KDM4EPOLB | |
| SCHEMBL6032172 | 0.63 | MAPT (0.53) | PPARGMAPTMCL1KDM4EALDH1A1 | |
| SCHEMBL6037063 | 0.62 | MAPT (0.52) | PPARGMAPTMCL1KDM4EALDH1A1 | |
| SCHEMBL1361452 | 0.62 | F2 (0.39) | MAPTKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | PPARG 1111/4885MAPT 3203/4885MCL1 4795/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | PPARG 1111/4885MAPT 3203/4885MCL1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.